PathAI partners with Discovery Life Sciences to deploy first AI-powered biospecimen solutions
PathAI announced a strategic partnership with Discovery Life Sciences, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.
Through this partnership, Discovery will deploy PathAI’s AISight Image Management System (IMS), ArtifactDetect, and TumorDetect products globally across its biospecimens business. In doing so, Discovery will help transform their traditional pathology workflow, significantly saving pathologists' time by automating routine tasks and analysis and allowing pathologists to focus on more complex tasks. Discovery will also empower customers with additional quantitative, tissue-level insights to provide more confident and standardized structured data from their biospecimens.
Building on this deployment, the companies will collaborate to develop a custom AI-driven tissue analysis panel exclusive to Discovery, further advancing translational research and biomarker discovery for biopharma partners. Looking beyond applications within Discovery’s biospecimens business, this partnership will allow for further exploration within Discovery’s Specialty Lab Services business, leveraging AI-driven solutions to deliver deeper insights to accelerate drug development and precision medicine initiatives.
